Oxylone
(Fluorometholone)ApprovedSmall molecule
AbbVieOxylone is one of 32 small molecule programs targeting Myopia. It is currently in Approved.
2
Indications
7
Total Trials
0
Active Trials
31
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
58 competitors in Myopia
#DrugCompanyPhaseTrials
1Atropen
FFresenius Kabi Oncology Ltd.
Approved
Alphagan
NovartisApproved
Isopto Carpine
AAdvanz Pharma
Approved
Mitosol
UUroGen Pharma Ltd.
Approved
Lucentis
RochePhase 3
Mydriacyl
FFalcon
Approved
Lotemax
PPharmos
Approved
Oxylone
AbbVieApproved
Avastin
BBio-Thera Solutions
Phase 3
Carboxymethylcellulose
AbbVieApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Rejection1 trial
Pterygium1 trial
Non-steroidal Anti-inflammatory Drugs1 trial
2 more indications
Myopia1 trial
Safety and Efficacy of Lotemax Versus FML in Subjects Undergoing PRK for the Correction of Mild to Moderate Myopia, 3- Month Follow-up Study
Unknown status·—·Phase 4·NCT02974387·200 enrolled
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
OXYLONE
NDA NDA011748
Jul 28, 1982
FML
NDA NDA016851
Sep 4, 1985
FML
NDA NDA017760
Feb 11, 1986
FLAREX
NDA NDA019079
Apr 23, 1986
FML FORTE
NDA NDA019216
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fluorometholone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]